Characterization of a recombinant humanized anti-cocaine monoclonal antibody and its Fab fragment

References

• Beck A, Wagner-Rousset E, Ayoub D, Van Dorsselaer A, Sanglier-Cianferani S. Characterization of therapeutic antibodies and related products. Anal Chem 2013; 85:715-36; PMID:23134362; http://dx.doi.org/10.1021/ac3032355
   PubMed Web of Science ®Google Scholar
• Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. Heterogeneity of monoclonal antibodies. J Pharm Sci 2008; 97:2426-47; PMID:17828757; http://dx.doi.org/10.1002/jps.21180
   PubMed Web of Science ®Google Scholar
• Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout BL. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnol J 2011; 6:38-44; PMID:20949542; http://dx.doi.org/10.1002/biot.201000091
   PubMed Web of Science ®Google Scholar
• Broussas M, Broyer L, Goetsch L. Evaluation of antibody-dependent cell cytotoxicity using lactate dehydrogenase (LDH) measurement. Methods Mol Biol 2013; 988:305-17; PMID:23475728; http://dx.doi.org/10.1007/978-1-62703-327-5_19
   PubMedGoogle Scholar
• Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, Flynn GC. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 2011; 21:949-59; PMID:21421994; http://dx.doi.org/10.1093/glycob/cwr027
   PubMed Web of Science ®Google Scholar
• Sreedhara A, Cordoba A, Zhu Q, Kwong J, Liu J. Characterization of the isomerization products of aspartate residues at two different sites in a monoclonal antibody. Pharm Res 2012; 29:187-97; PMID:21809161; http://dx.doi.org/10.1007/s11095-011-0534-2
   PubMed Web of Science ®Google Scholar
• Qi P, Volkin DB, Zhao H, Nedved ML, Hughes R, Bass R, Yi SC, Panek ME, Wang D, Dalmonte P, et al. Characterization of the photodegradation of a human IgG1 monoclonal antibody formulated as a high-concentration liquid dosage form. J Pharm Sci 2009; 98:3117-30; PMID:19009595; http://dx.doi.org/10.1002/jps.21617
   PubMedGoogle Scholar
• Lape M, Paula S, Ball WJ, Jr. A molecular model for cocaine binding by the immunotherapeutic human/mouse chimeric monoclonal antibody 2E2. Eur J Med Chem 2010; 45:2291-8; PMID:20185210; http://dx.doi.org/10.1016/j.ejmech.2010.02.004
   PubMedGoogle Scholar
• Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol 2005; 23:1117-25; PMID:16151405; http://dx.doi.org/10.1038/nbt1135
   PubMed Web of Science ®Google Scholar
• Norman AB, Tabet MR, Norman MK, Buesing WR, Pesce AJ, Ball WJ. A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice. J Pharm Exp Ther 2007; 320:145-53; PMID:17023573; http://dx.doi.org/10.1124/jpet.106.111781
   PubMedGoogle Scholar
• Norman AB, Gooden FC, Tabet MR, Ball WJ. A recombinant humanized anti-cocaine monoclonal antibody inhibits the distribution of cocaine to the brain in rats. Drug Metab Dispos 2014; 42:1125-31; PMID:24733787; http://dx.doi.org/10.1124/dmd.114.057034
   PubMedGoogle Scholar
• Gadgil HS, Bondarenko PV, Pipes G, Rehder D, McAuley A, Perico N, Dillon T, Ricci M, Treuheit M The LC/MS analysis of glycation of IgG molecules in sucrose containing formulations. J Pharm Sci 2007; 96:2607-21; PMID:17621682; http://dx.doi.org/10.1002/jps.20966
   PubMed Web of Science ®Google Scholar
• Ren D, Pipes G, Xiao G, Kleemann GR, Bondarenko PV, Treuheit MJ, Gadgil HS. Reversed-phase liquid chromatography-mass spectrometry of site-specific chemical modifications in intact immunoglobulin molecules and their fragments. J Chromatogr A 2008; 1179:198-204; PMID:18096172; http://dx.doi.org/10.1016/j.chroma.2007.11.088
   PubMed Web of Science ®Google Scholar
• Raju TS. Glycosylation variations with expression systems and their impact on biological activity of therapeutic immunoglobulins. BioProcess Int 2003; April:44-53.
   Google Scholar
• Maley F, Trimble RB, Tarentino AL, Plummer TH, Jr. Characterization of glycoproteins and their associated oligosaccharides through the use of endoglycosidases. Anal Biochem 1989; 180:195-204; PMID:2510544; http://dx.doi.org/10.1016/0003-2697(89)90115-2
   PubMed Web of Science ®Google Scholar
• Mullan B, Dravis B, Lim A, Clarke A, Janes S, Lambooy P, Olson D, O'Riordan T, Ricart B, Tulloch AG. Disulphide bond reduction of a therapeutic monoclonal antibody during cell culture manufacturing operations. BMC Proc 2011; 5 Suppl 8:P110; http://dx.doi.org/10.1186/1753-6561-5-S8-P110
   Google Scholar
• Liu H, May K. Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. mAbs 2012; 4:17-23; PMID:22327427; http://dx.doi.org/10.4161/mabs.4.1.18347
   PubMed Web of Science ®Google Scholar
• Liu H, Chumsae C, Gaza-Bulseco G, Hurkmans K, Radziejewski CH. Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis. Anal Chem 2010; 82:5219-26; PMID:20491447; http://dx.doi.org/10.1021/ac100575n
   PubMed Web of Science ®Google Scholar
• Husted LB, Sorensen ES, Sottrup-Jensen L. 4-(Aminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole is not specific for labeling of sulfhydryl groups in proteins as it may also react with phenolic hydroxyl groups and amino groups. Anal Bioch 2003; 314:166-8; PMID:12633619; http://dx.doi.org/10.1016/S0003-2697(02)00650-4
   PubMedGoogle Scholar
• Lau H, Pace D, Yan B, McGrath T, Smallwood S, Patel K, Park J, Park SS, Latypov RF. Investigation of degradation processes in IgG1 monoclonal antibodies by limited proteolysis coupled with weak cation-exchange HPLC. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:868-76; PMID:20206584; http://dx.doi.org/10.1016/j.jchromb.2010.02.003
   PubMed Web of Science ®Google Scholar
• Kleemann GR, Beierle J, Nichols AC, Dillon TM, Pipes GD, Bondarenko PV. Characterization of IgG1 immunoglobulins and peptide-Fc fusion proteins by limited proteolysis in conjunction with LC-MS. Anal Chem 2008; 80:2001-9; PMID:18293943; http://dx.doi.org/10.1021/ac701629v
   PubMedGoogle Scholar
• Tetin SY, Hazlett TL. Optical spectroscopy in studies of antibody-hapten interactions. Methods 2000; 20:341-61; PMID:10694456; http://dx.doi.org/10.1006/meth.1999.0927
   PubMedGoogle Scholar
• Nakayama H, Kenjyou N, Shigetoh N. A novel monoclonal antibody specific for cocaine. Monoclon Antib Immunodiagn Immunother 2013; 32:262-4; PMID:23909419; http://dx.doi.org/10.1089/mab.2013.0002
   PubMedGoogle Scholar
• Bleck GT. Consistent production of genetically stable mammalian cell lines. BioPharm Int 2012; 25:56-9.
   Web of Science ®Google Scholar
• Kirley TL. Reduction and fluorescent labeling of cyst(e)ine-containing proteins for subsequent structural analyses. Anal Biochem 1989; 180:231-6; PMID:2554752; http://dx.doi.org/10.1016/0003-2697(89)90422-3
   PubMedGoogle Scholar
• Toyo'oka T, Imai K. Isolation and characterization of cysteine-containing regions of proteins using 4-(Aminosulfonyl)-7-2,1,3-benzoxadiazole and high-performance liquid chromatography. Anal Chem 1985; 57:1931-7; PMID:4037347; http://dx.doi.org/10.1021/ac00286a032
   PubMed Web of Science ®Google Scholar
• O'Farrell PZ, Goodman HM, O'Farrell PH. High resolution two-dimensional electrophoresis of basic as well as acidic proteins. Cell 1977; 12:1133-41; PMID:23215; http://dx.doi.org/10.1016/0092-8674(77)90176-3
   PubMed Web of Science ®Google Scholar